|24.16||-0.0300||-0.12%||Vol 595.62K||1Y Perf 72.57%|
|Apr 9th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||35.00||Analyst Rating||Strong Buy 1.10|
|Potential %||44.87||Finscreener Ranking||★★ 46.59|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★ 40.27|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★ 53.34|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Market Cap||1.72B||Earnings Rating||Strong Sell|
|Price Range Ratio 52W %||64.95||Earnings Date||5th May 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||5th May 2021|
|Estimated EPS Next Report||-0.59|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||699.13K|
|Avg. Monthly Volume||911.33K|
|Avg. Quarterly Volume||924.27K|
Cytokinetics Incorporated (NASDAQ: CYTK) stock closed at 24.16 per share at the end of the most recent trading day (a -0.12% change compared to the prior day closing price) with a volume of 598.05K shares and market capitalization of 1.72B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 156 people. Cytokinetics Incorporated CEO is Robert I. Blum.
The one-year performance of Cytokinetics Incorporated stock is 72.57%, while year-to-date (YTD) performance is 16.27%. CYTK stock has a five-year performance of 213.36%. Its 52-week range is between 13.08 and 30.14, which gives CYTK stock a 52-week price range ratio of 64.95%
Cytokinetics Incorporated currently has a PE ratio of -12.10, a price-to-book (PB) ratio of 14.59, a price-to-sale (PS) ratio of 34.36, a price to cashflow ratio of 167.80, a PEG ratio of 2.32, a ROA of -29.97%, a ROC of -50.33% and a ROE of -250.88%. The company’s profit margin is -%, its EBITDA margin is -155.40%, and its revenue ttm is $52.00 Million , which makes it $0.73 revenue per share.
Of the last four earnings reports from Cytokinetics Incorporated, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.59 for the next earnings report. Cytokinetics Incorporated’s next earnings report date is 05th May 2021.
The consensus rating of Wall Street analysts for Cytokinetics Incorporated is Strong Buy (1.1), with a target price of $35, which is +44.87% compared to the current price. The earnings rating for Cytokinetics Incorporated stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Cytokinetics Incorporated has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Cytokinetics Incorporated has a Buy technical analysis rating based on Technical Indicators (ADX : 9.05, ATR14 : 1.40, CCI20 : -50.45, Chaikin Money Flow : -0.34, MACD : -0.52, Money Flow Index : 50.43, ROC : -4.56, RSI : 46.04, STOCH (14,3) : 35.06, STOCH RSI : 1.00, UO : 42.69, Williams %R : -64.94), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Cytokinetics Incorporated in the last 12-months were: B. Lynne Parshall (Option Excercise at a value of $387 993), B. Lynne Parshall (Sold 63 331 shares of value $1 734 830 ), Ching Jaw (Option Excercise at a value of $464 100), Ching Jaw (Sold 52 500 shares of value $1 450 000 ), David W. Cragg (Option Excercise at a value of $156 994), Edward M. Kaye (Option Excercise at a value of $152 200), Edward M. Kaye (Sold 20 000 shares of value $600 000 ), Fady Ibraham Malik (Option Excercise at a value of $117 750), Fady Ibraham Malik (Sold 22 854 shares of value $461 364 ), John T. Henderson (Option Excercise at a value of $162 242), John T. Henderson (Sold 4 591 shares of value $112 259 ), L. Patrick Gage (Option Excercise at a value of $56 194), Leonard Patrick Gage (Option Excercise at a value of $284 986), Leonard Patrick Gage (Sold 28 055 shares of value $625 878 ), Mark A. Schlossberg (Option Excercise at a value of $140 600), Mark A. Schlossberg (Sold 20 000 shares of value $480 728 ), Robert I. Blum (Option Excercise at a value of $1 564 902), Robert I. Blum (Sold 135 000 shares of value $2 811 876 ), Sandford Drexel Smith (Option Excercise at a value of $734 982), Sandford Drexel Smith (Sold 126 192 shares of value $3 120 443 ), Santo J. Costa (Option Excercise at a value of $1 000 817), Santo J. Costa (Sold 123 330 shares of value $2 781 017 ), Wendell D. Wierenga (Option Excercise at a value of $204 780), Wendell D. Wierenga (Sold 19 998 shares of value $319 968 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.